Product Code: RP-ID-10149146 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10149146
Market Overview:
Global Protein Powder Market - Analysis By Type (Whey, Casein, Soy, Hemp, Others), Application (Food & Beverage, Healthcare, Sports Nutrition, Others), Distribution Channel (Online, Offline), By Region, By CountryOpportunities and Forecast 2022-2030
" The global Prader-Willi syndrome market is expected to expand at a compound annual growth rate of ~5% during the forecast period (2022-2030). Prader-Willi syndrome (PWS) is a genetic disease caused by the elimination of part of the father. Chromosome 15. Prader-Willi syndrome may also be due to the presence of two copies of chromosome 15 inherited only from the mother, causing it to be deleted during gene formation. PWS therapy has wide-ranging influence in the global market because there is no known cure for this complex genetic disease.
MARKET DYNAMICS:
The main driving forces are the increase in the number of special drugs designated by regulatory agencies, the increase in the number of confirmed patients, the increase in human growth hormone treatment coverage, the strong project portfolio, the growth of strategic alliances, the use of advanced technology to diagnose and treat PWS, and the growing awareness.
The increasing prevalence of Prader-Willi syndrome is expected to drive market growth. For example, the National Institutes of Health reports that Prader-Willi syndrome affects approximately 1 in 10,000 to 30,000 people worldwide. According to the International Prader-Willi Syndrome Organization, 1 in 12,000 to 15,000 people has Prader-Willi Syndrome. It has been recognized as the most common disease and common genetic cause of obesity in genetic clinics. Therefore, the increasing prevalence of Prader Willy syndrome is driving the market.
The presence of government organizations that are developing PWS therapies is driving the market. For example, the Prader-Willi Research Foundation is an active organization that has been working to develop treatments for Prader-Willi syndrome. It has been funding certain research activities that are investigating various methods of treating or overcoming Prader Willi syndrome, such as gene therapy, obesity drugs, behavioral and appetite drugs, and devices. However, all of these are still in the development stage. It is expected that a strong investment portfolio will drive the market during the forecast period.
However, the limited efficacy of current therapies, lack of understanding of Prader Willy syndrome, and the existence of disease-related complications are expected to slow down market growth. Market growth. Due to low awareness of PWS, it is difficult to realize the sale of potential products. Despite effective treatments, personal attitudes, beliefs, poor treatment compliance, and insufficient communication between doctors and patients about PWS are hindering market growth. Common clinical complications in PWS include excessive daytime sleepiness, scoliosis, osteopenia/osteoporosis, decreased exercise capacity, sleep disturbance, and decreased sensitivity to pain.
MARKET SEGMENTATION:
According to product types, the global market for Prader-Willi syndrome is divided into Belonib, Betahistine Hydrochloride, Diazoxide Choline CR, FE-992097, Recombinant Growth Hormone, etc. High interest rates during the forecast period. At present, the medical treatment of Pradwill syndrome (PWS) is mainly focused on the use of human growth hormone (HGH) supplements approved in the United States. Since growth hormone (GH) deficiency is almost universal in patients with PWS, the treatment market is sluggish. Some of the most approved GH treatments include Pfizers Genotropin (growth hormone) and other major brands such as Norditropin (Novo Nordisk) and some other brands in the United States. Another approved drug is Sandozs Omnitrope (growth hormone injection [rDNA source]).
In addition, ongoing clinical trials of growth hormone are expected to drive market growth. For example, due to the existence of R&D activities, the beloranib part is also expected to drive market growth during the forecast period. For example, lead researcher Dr. Merlin G. Butler reported at the annual meeting of the Endocrine Society that in 2016, patients with Prader-Willi syndrome (PWS) lost more than 4% of their weight. The term is 26 years. In the phase 3 trial of the best PWS, the investigative anti-obesity drug beloranib was one week, compared with patients taking placebo to obtain similar benefits.
In addition, hunger-related behaviors, total cholesterol and low-density lipoprotein cholesterol levels, and other cardiometabolic risk factors were also reduced. Therefore, beloranib R&D activities are driving the market. Due to the existence of major players in the production of betahistine, the betahistine part is expected to grow rapidly during the forecast period.
For example, on December 6, 2018, Auris Medical Holding AG is a clinical-stage company dedicated to the development of treatments that address key unmet needs in neurology and mental health support care, and announced a strategic expansion of the development plan. In 2 related transactions, the company obtained the orphan drug qualification for betahistine to treat obesity related to Prader-Willi syndrome (PWS), and signed a binding letter of intent to license 2 patents Exclusive right. They are depression and attention deficit/hyperactivity disorder (ADHD).
GEOGRAPHICAL ANALYSIS :
Geographically, the global Pradwill syndrome market is divided into five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominated the global Prader-Willi syndrome market in 2020, and due to the increasing prevalence of Prader-Willi syndrome in the region, it is expected to have a considerable Market size. Research and development activities on Prader Willy Syndrome are ongoing. Raising awareness of PWS in the region is also expected to drive market growth. For example, the Prader-Willi Syndrome Association (USA) has been providing life-saving research, crisis and family support, medical treatment, and new parenting support since 1975. It is expected to promote market growth during the forecast period 2022-2030."
Abbot Laboratories, GlaxoSmithKline Plc, AMCO Proteins, MusclePharm Corporation, NOW Foods, Glanbia Plc, NBTY Inc, Herbalife International of America, Inc., General Nutrition Corporation (GNC Holdings Inc.), Suppleform
Related Reports
Proof of Quality & Reliability
